Srpski arhiv za celokupno lekarstvo 2011 Volume 139, Issue 7-8, Pages: 514-517
https://doi.org/10.2298/SARH1108514M
Full text ( 212 KB)
Cited by
Anti-TNF treatment and miliary tuberculosis in Crohn’s disease
Milenković Branislava (Medicinski fakultet, Beograd + Klinika za plućne bolesti i tuberkulozu, Klinički centar Srbije, Beograd)
Dudvarski-Ilić Aleksandra (Medicinski fakultet, Beograd + Klinika za plućne bolesti i tuberkulozu, Klinički centar Srbije, Beograd)
Janković Goran (Klinika za plućne bolesti i tuberkulozu, Klinički centar Srbije, Beograd + Klinika za gastroenterologiju i hepatologiju, Klinički centar Srbije, Beograd)
Martinović Lena (Klinika za gastroenterologiju i hepatologiju, Klinički centar Srbije, Beograd)
Mijač Dragana (Klinika za gastroenterologiju i hepatologiju, Klinički centar Srbije, Beograd)
Introdution. Tumour necrosis factor alpha (TNFα) has a central role in the
host immune response to mycobacterial infection. TNFα blockade may therefore
result in reactivation of recent or remotely acquired infection. In reported
mycobacterium tuberculosis infections, extra-pulmonary and disseminated
tuberculosis (TB) was common, appeared rapidly, and if unrecognized, with
fatal outcome. We present a female patient with miliary TB following
treatment with infliximab for fistulizing Crohn’s disease. Case Outline. Five
years before admission, the patient was diagnosed with Crohn’s disease, with
inflammation limited to the terminal ileum and sigmoid colon and has been on
azathioprine 100 mg/day for the last 10 months. Three months before admission
to the hospital she developed an enterocutaneous fistula for which therapy
with infliximab was started in addition to azathioprine therapy. A tuberculin
skin test and a chest x-ray were performed prior to the first infusion with
normal findings. She presented with a 6-week history of fever, weakness,
weight-loss and a 2-week dry cough. Chest x-ray and computed tomography
displayed remarkable bilateral hilar and mediastinal lymphadenopathy and
uniformly distributed fine nodules throughout both lung fields varying in
size from 2 to 3 mm, without any signs of cavitation. Since there were
clinical and morphological signs that indicated miliary TB, the treatment
with antituberculous therapy was started and six weeks later all of the
symptoms completely resolved and the lesions visible on x-ray diminished.
Conclusion. The clinical use of TNF-inhibitors is associated with increased
risk of developing tuberculosis. Physicians should be aware of the increased
risk of reactivation of TB among patients treated with anti-TNF agents and
regularly look for usual and unusual symptoms of TB.
Keywords: infliximab, Crohn’s disease, tuberculosis
More data about this article available through SCIndeks